pozelimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
pozelimab

GtoPdb Ligand ID: 12900

Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®

pozelimab is an approved drug (FDA (2023))

Compound class: Antibody

Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
An anti-C5 mAb that is proposed to treat inflammatory disorders that are driven complement pathway activation.

Immunopharmacology Comments

An anti-C5 mAb that is proposed to treat inflammatory disorders that are driven complement pathway activation.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
CHAPLE disorder; CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)	OMIM: 226300 Orphanet: ORPHA566175	Pozelimab is FDA aproved to treat children and adults with CHAPLE disorder.